Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTR20132891
CTR20132891Active, not recruitingPhase 3

注射用鼠神经生长因子治疗视神经损伤多中心、随机、双盲、安慰剂合并基础治疗、平行对照的Ⅲ期临床试验

Not provided24 sites in 1 country480 target enrollmentStarted: February 25, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Status
Active, not recruiting
Enrollment
480
Locations
24
Primary Endpoint
综合疗效评分
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Detailed Description

评价注射用鼠神经生长因子（恩经复）30 μg（≥15000 AU）/支治疗视神经损伤的有效性和安全性。

Study Design

Study Type
安全性和有效性
Allocation
随机化
Intervention Model
平行分组
Masking
双盲

Eligibility Criteria

Ages
18岁(最小年龄) to 70岁(最大年龄) (—)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

综合疗效评分

Time Frame: 0 天，21 天，42 天

最佳矫正视力

Time Frame: 0 天，21 天，42 天

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Not provided
Responsible Party
Sponsor
Principal Investigator

齐健

厦门北大之路生物工程有限公司

Study Sites (24)

Loading locations...

Similar Trials

Active, not recruiting
Phase 2
注射用重组人神经生长因子在非动脉炎性前部缺血性视神经病变患者 中的多中心、随机、双盲、安慰剂平行对照 II 期临床试验
CTR20232035180
Active, not recruiting
Phase 2
重组人神经生长因子（ZX1305）注射液Ⅱ期临床研究
CTR20230387180
Active, not recruiting
Phase 2
重组人神经生长因子滴眼液 II 期临床试验
CTR20251509156
Completed
Phase 2
评价注射用鼠神经生长因子有效性和安全性研究
CTR2017019590
Suspended
Phase 3
重组人纽兰格林对慢性心衰患者死亡率的 III 期临床试验
CTR201303561,600